Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | adrenoceptor beta 3 | Starlite/ChEMBL | References |
Homo sapiens | adrenoceptor beta 2, surface | Starlite/ChEMBL | References |
Homo sapiens | adrenoceptor beta 1 | Starlite/ChEMBL | References |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activation (functional) | = 67 % | Agonistic activity towards Beta-3 adrenergic receptor was measured as adenylyl cyclase activation given as % of the maximal stimulation with isoproterenol | ChEMBL. | 10201842 |
Activation (functional) | = 67 % | Agonistic activity towards Beta-3 adrenergic receptor was measured as adenylyl cyclase activation given as % of the maximal stimulation with isoproterenol | ChEMBL. | 10201842 |
EC50 (functional) | = 5.9 nM | Agonist activity towards Beta-3 adrenergic receptor | ChEMBL. | 10201842 |
EC50 (functional) | = 5.9 nM | Agonist activity towards Beta-3 adrenergic receptor | ChEMBL. | 10201842 |
IC50 (binding) | = 5000 nM | Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]-iodocyanopindolol | ChEMBL. | 10201842 |
IC50 (binding) | = 5000 nM | Binding affinity towards human Beta-2 adrenergic receptor expressed in CHO cells, using [125I]-iodocyanopindolol | ChEMBL. | 10201842 |
IC50 (binding) | = 8500 nM | Binding affinity towards human Beta-1 adrenergic receptor expressed in CHO cells, using 1251-iodocyanopindolol | ChEMBL. | 10201842 |
IC50 (binding) | = 8500 nM | Binding affinity towards human Beta-1 adrenergic receptor expressed in CHO cells, using 1251-iodocyanopindolol | ChEMBL. | 10201842 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.